StreetInsider.com News Articles

Cellectar publishes Phase 1 data on iopofosine I 131 in myeloma patients

Wed, 15 Jul 2026 07:30:16 -0400

Cellectar Biosciences (NASDAQ: CLRB) announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 combined with low-dose dexamethasone in 31 patients with relapsed or refractory multiple myeloma. The manuscript appeared in the peer-reviewed journal Cancers.

The open-label, multi-center trial enrolled patients who had received a median of four prior lines of therapy. Among 26 efficacy-evaluable patients, 84.6% achieved stable disease or better. The overall response rate was 15.4%, with four patients achieving partial responses. Among patients receiving at least 60 mCi of iopofosine I 131, the overall response rate rose to 30%.

Adverse events were primarily hematologic,

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Wed, 15 Jul 2026 07:30:00 -0400

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in
Relapsed/Refractory Multiple Myeloma

Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted
Radiotherapeutic Across Multiple B-Cell Malignancies

FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma (r/r MM).

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Wed, 15 Jul 2026 07:30:00 -0400

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in
Relapsed/Refractory Multiple Myeloma

Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted
Radiotherapeutic Across Multiple B-Cell Malignancies

Brookline Capital Markets Reinstates Cellectar Biosciences (CLRB) at Buy

Mon, 13 Jul 2026 04:51:14 -0400

Brookline Capital Markets analyst Kumaraguru Raja reinstates coverage on Cellectar Biosciences (NASDAQ: CLRB) with a Buy rating and a price target of $15.00.

For an analyst ratings summary and ratings history on Cellectar Biosciences click here. For more ratings news on Cellectar Biosciences click here.

Shares of Cellectar Biosciences closed at $2.82 yesterday.

Form 4/A Cellectar Biosciences, For: Jul 08 Filed by: Loren Stefan

Fri, 10 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758303.html

Form 4/A Cellectar Biosciences, For: Jul 08 Filed by: Loren Stefan

Fri, 10 Jul 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758303.html

Form 8-K Cellectar Biosciences, For: Jul 07

Fri, 10 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260710/26758021.html

Form 8-K Cellectar Biosciences, For: Jul 07

Fri, 10 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260710/26758021.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Kolean Chad J

Wed, 08 Jul 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260708/26748832.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Kolean Chad J

Wed, 08 Jul 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260708/26748832.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: DRISCOLL FREDERICK W

Wed, 08 Jul 2026 21:10:00 -0400

si-local-file:///var/storage/secattach/20260708/26748828.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: DRISCOLL FREDERICK W

Wed, 08 Jul 2026 21:10:00 -0400

si-local-file:///var/storage/secattach/20260708/26748828.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Chanan-Khan Asher

Wed, 08 Jul 2026 21:09:00 -0400

si-local-file:///var/storage/secattach/20260708/26748826.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Chanan-Khan Asher

Wed, 08 Jul 2026 21:09:00 -0400

si-local-file:///var/storage/secattach/20260708/26748826.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: CARUSO JAMES V

Wed, 08 Jul 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260708/26748825.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: CARUSO JAMES V

Wed, 08 Jul 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260708/26748825.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Gu Andrew

Wed, 08 Jul 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260708/26748824.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Gu Andrew

Wed, 08 Jul 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260708/26748824.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Longcor Jarrod

Wed, 08 Jul 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26748823.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Longcor Jarrod

Wed, 08 Jul 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260708/26748823.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Swirsky Douglas J

Wed, 08 Jul 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26748821.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: Swirsky Douglas J

Wed, 08 Jul 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26748821.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: NEIS JOHN

Wed, 08 Jul 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260708/26748818.html

Form 4 Cellectar Biosciences, For: Jul 07 Filed by: NEIS JOHN

Wed, 08 Jul 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260708/26748818.html

Form 4 Cellectar Biosciences, For: Jul 08 Filed by: Loren Stefan

Wed, 08 Jul 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260708/26748815.html